
Altimmune (ALT) Stock Forecast & Price Target
Altimmune (ALT) Analyst Ratings
Bulls say
Altimmune Inc. demonstrates a positive outlook due to pemvidutide's significant clinical results, including weight loss of up to 6.2% at 24 weeks and substantial liver fat reduction of up to 62.8%, alongside notable improvements in histological endpoints and biomarker measures. The evidence of anti-fibrotic activity, as indicated by reductions in ELF and VCTE scores, supports the drug's potential effectiveness in treating metabolic-associated steatohepatitis (MASH). Additionally, the strengthening of Altimmune's leadership team positions the company well for key upcoming catalysts, further enhancing confidence in pemvidutide's advancement to Phase 3 trials.
Bears say
Altimmune Inc. is currently experiencing a significant decline in its stock value, with shares down approximately 55%, despite its promising clinical prospects for its product candidate, pemvidutide, aimed at treating obesity and metabolic-associated steatohepatitis. The company faces multiple risks that contribute to a negative outlook, including clinical development, commercialization, competitor challenges, reimbursement uncertainties, and potential capital market dilution. Additionally, external factors such as potential COVID-19 disruptions and geopolitical tensions from the ongoing war in Eastern Europe further exacerbate the uncertainties surrounding Altimmune's financial stability and future prospects.
This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.
Altimmune (ALT) Analyst Forecast & Price Prediction
Start investing in Altimmune (ALT)
Order type
Buy in
Order amount
Est. shares
0 shares